You are viewing: Spain Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The Spain Leukapheresis Market was valued at $1.06 Million in 2026 and projected to reach to $1.52 Million by 2031, representing a compound annual growth rate of CAGR 7.4%. Spain's leukapheresis market is poised for steady growth driven by the expansion of cell therapy programs across major Spanish hospitals and research institutions.

Spain Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Spain Leukapheresis Market Trends and Insights

  • Spain's healthcare infrastructure and increasing adoption of advanced cell therapy technologies are driving demand for leukapheresis procedures across hematologic and oncologic applications.
  • The Spanish market benefits from strong regulatory frameworks and growing investment in immunotherapy treatments, positioning Spain as a key player in Europe's cell collection and processing sector. During the forecast period from 2026 to 2031, Spain is expected to experience steady market expansion driven by rising prevalence of blood cancers and autoimmune disorders requiring leukapheresis intervention.
  • Spain's healthcare system's commitment to precision medicine and regenerative therapies supports the adoption of leukapheresis equipment and consumables.
  • Market growth in Spain will be supported by increasing clinical awareness among Spanish healthcare providers and patient access to CAR-T cell therapies and other cell-based treatments that depend on efficient leukapheresis procedures..

Key Market Statistics

  • CAGR (2026-2031) CAGR 7.4%
  • Market Size, 2026 ~USD 1.06 Million
  • Forecast, 2031 ~USD 1.52 Million
  • Country Spain

Spain Leukapheresis Market Overview

Market Size & Growth :

Spain's leukapheresis market is valued at USD 1.06 million in 2026, expanding to USD 1.52 million by 2031 at a CAGR of 7.4%, outpacing broader European adoption rates.

Healthcare Infrastructure Advancement :

Spain's robust healthcare system and investment in specialized oncology and hematology centers are accelerating the adoption of leukapheresis technologies for cell therapy applications.

Cell Therapy Expansion :

Increasing clinical trials and regulatory approvals for CAR-T and other advanced cell therapies in Spain are driving demand for efficient leukapheresis procedures in treatment protocols.

Regional Market Positioning :

Spain represents a key growth market within Southern Europe, with rising healthcare expenditure and government support for innovative cancer treatment modalities strengthening market fundamentals.

Spain Leukapheresis Market Dynamics

  • The country's commitment to precision medicine and oncology innovation, coupled with increasing patient awareness of advanced treatment options, supports sustained demand for leukapheresis procedures.
  • Healthcare reimbursement policies and collaborations between Spanish medical centers and international biotech firms are expected to accelerate market penetration. The forecast period through 2031 will likely see enhanced adoption of automated leukapheresis systems and integration with CAR-T cell manufacturing workflows.
  • Spain's aging population and rising cancer incidence rates further underscore the clinical need for efficient cell collection technologies.
  • Strategic investments in hematology departments and growing partnerships with global cell therapy manufacturers position Spain as an emerging hub for advanced apheresis procedures in Southern Europe..

Related Ecosystem

Key Takeaways

  • Spain's leukapheresis market is valued at USD 1.06 million in 2026 and will reach USD 1.52 million by 2031 at a 7.4% CAGR.
  • Spain's advanced healthcare infrastructure and regulatory environment support adoption of cell therapy technologies requiring leukapheresis.
  • Rising incidence of hematologic malignancies and autoimmune diseases in Spain is driving demand for leukapheresis procedures.
  • Spain's commitment to precision medicine and CAR-T cell therapy access will accelerate leukapheresis market growth through 2031.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

Spain Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

Target Audience

  • Medical Device Manufacturers : Leukapheresis equipment and apheresis system providers need Spain-specific market data to assess demand, competitive positioning, and sales forecasting for Spanish healthcare facilities.
  • Cell Therapy Companies : CAR-T and advanced cell therapy developers require insights into Spanish clinical adoption rates, hospital partnerships, and procedure volumes to support manufacturing and distribution strategies.
  • Healthcare Investors & PE Firms : Investment professionals evaluating Spanish healthcare assets need localized market growth data, CAGR trends, and opportunity analysis to support due diligence and portfolio decisions.
  • Hospital & Clinic Administrators : Spanish oncology and hematology center leaders need market intelligence on leukapheresis demand, technology trends, and reimbursement models to guide capital investment and service expansion.
  • Market Research & Consulting Firms : Research organizations and consultants serving healthcare clients require Spain-specific leukapheresis data to support client advisory work, competitive analysis, and market strategy recommendations.

Key Companies in the Spain Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • Localized Market Intelligence : Gain Spain-specific insights on leukapheresis adoption rates, clinical applications, and market dynamics unavailable in global reports, enabling targeted business strategy development.
  • Competitive Landscape Analysis : Understand key Spanish healthcare providers, equipment suppliers, and cell therapy centers operating in the leukapheresis space to identify partnership and expansion opportunities.
  • Regulatory & Reimbursement Clarity : Access detailed information on Spanish healthcare regulations, reimbursement policies, and approval pathways specific to leukapheresis and cell therapy procedures.
  • Growth Opportunity Identification : Identify high-potential segments within Spain's market, including emerging applications, underserved regions, and technology adoption gaps for strategic investment planning.
  • Forecast-Driven Planning : Leverage Spain-specific CAGR projections and market size forecasts through 2031 to inform product development, market entry timing, and resource allocation decisions.

Frequently asked questions

What is the current size of Spain's leukapheresis market?

Spain's leukapheresis market is estimated at USD 1.06 million in 2026.

What is the projected market size for Spain's leukapheresis market by 2031?

Spain's leukapheresis market is projected to reach USD 1.52 million by 2031.

What is the CAGR for Spain's leukapheresis market?

Spain's leukapheresis market is expected to grow at a compound annual growth rate (CAGR) of 7.4% from 2026 to 2031.

What factors are driving growth in Spain's leukapheresis market?

Growth in Spain's leukapheresis market is driven by rising prevalence of blood cancers, increasing adoption of CAR-T cell therapies, and Spain's commitment to precision medicine and advanced cell therapy technologies.

How does Spain's healthcare system support leukapheresis adoption?

Spain's advanced healthcare infrastructure, strong regulatory frameworks, and investment in immunotherapy treatments create a favorable environment for leukapheresis equipment and consumable adoption.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status